Immunogenicity and safety of DS-5670d, an omicron XBB.1.5-targeting COVID-19 mRNA vaccine: A phase 3, randomized, active-controlled study
A single dose of DS-5670d was immunogenically non-inferior to BNT162b2 and acceptably safe in persons with or without a history of prior infection and/or vaccination. Trial registration Japan Registry of Clinical Trials (jRCT2031230424).
Authors
- Ami Kawamoto (ORCID: https://orcid.org/0000-0002-8549-4999)
- Katsuyasu Ishida
- Kei Furihata
- Masaki Hashida (ORCID: https://orcid.org/0000-0003-4834-0138)
- T. Nakano (ORCID: https://orcid.org/0000-0003-3157-5328)
- Kaori Takahashi
- Aisaku Ota
- Sachiko Sakakibara
- Fumihiko Takeshita (ORCID: https://orcid.org/0009-0001-7124-8877)
Institutions
- Kawasaki Medical School (JP)
- Daiichi-Sankyo (Japan) (JP)
Publication Details
- Journal
- PLoS Medicine
- Published
- 2025-10-13
- DOI
- https://doi.org/10.1371/journal.pmed.1004499
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Japan Agency for Medical Research and Development
- Daiichi-Sankyo
- Ministry of Health, Labour and Welfare
- Daiichi Sankyo Europe